Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | SDHA | P31040 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CALML3 | P27482 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 5/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19250587 | 0.89 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL22808193 | 0.87 | MAOA (0.67) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7531429 | 0.86 | MAOA (0.57) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL9521097 | 0.86 | MAOA (0.57) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL22808200 | 0.85 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL9550298 | 0.83 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL22808191 | 0.83 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL22808170 | 0.82 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL22808202 | 0.82 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4573665 | 0.80 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870646-B2 | Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis | UNIVERSITY OF ST. THOMAS (US) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870646-B2 | Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis | OXA1L, IMMT, TBCD | MAOA 1077/4885MAOB 668/4885PTGS1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.